Citigroup’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$561K Buy
182,610
+12,323
+7% +$47.6K ﹤0.01% 3479
2025
Q4
$696K Buy
170,287
+103,886
+156% +$515K ﹤0.01% 3374
2025
Q3
$324K Sell
66,401
-148,346
-69% -$779K ﹤0.01% 3775
2025
Q2
$1.09M Sell
214,747
-444,702
-67% -$2.18M ﹤0.01% 3142
2025
Q1
$3.49M Buy
659,449
+158,461
+32% +$1.16M ﹤0.01% 2236
2024
Q4
$3.39M Buy
500,988
+310,236
+163% +$2.09M ﹤0.01% 2348
2024
Q3
$1.26M Buy
190,752
+87,142
+84% +$625K ﹤0.01% 3074
2024
Q2
$777K Sell
103,610
-697,577
-87% -$6.08M ﹤0.01% 3080
2024
Q1
$7.99M Buy
801,187
+396,334
+98% +$4.41M 0.01% 1389
2023
Q4
$3.99M Sell
404,853
-65,659
-14% -$468K 0.01% 1735
2023
Q3
$3.6M Buy
470,512
+293,174
+165% +$2.92M 0.01% 1607
2023
Q2
$1.32M Sell
177,338
-510,887
-74% -$3.57M ﹤0.01% 2602
2023
Q1
$4.59M Buy
688,225
+455,398
+196% +$3.61M 0.01% 1547
2022
Q4
$1.8M Buy
232,827
+71,267
+44% +$699K ﹤0.01% 2124
2022
Q3
$1.72M Buy
161,560
+149,260
+1,213% +$1.51M ﹤0.01% 2265
2022
Q2
$100K Sell
12,300
-2,599
-17% -$17.4K ﹤0.01% 4225
2022
Q1
$106K Sell
14,899
-229,458
-94% -$2.44M ﹤0.01% 4387
2021
Q4
$4.19M Buy
244,357
+199,063
+439% +$3.75M ﹤0.01% 1967
2021
Q3
$1.04M Buy
45,294
+44,288
+4,402% +$1.26M ﹤0.01% 3051
2021
Q2
$37K Buy
+1,006
New +$29.8K ﹤0.01% 4961

Other funds holding RXRX